The bioanalytical contract research organization (CRO) market is more competitive than ever. Sponsors have more choices, timelines are tighter, and the complexity of the programmes they hand over to CROs has increased sharply. Monoclonal antibodies (mAbs), fusion proteins, antibody-drug conjugates (ADCs), bispecifics, and gene therapy vectors all require rigorous ligand-binding assay (LBA) support and sponsors evaluating CRO partners are asking not just whether you can run the assay, but how you run it, and whether your data will hold up under regulatory scrutiny.
Gyrolab® is not an incremental improvement on conventional ligand-binding assay platforms. It delivers a fundamentally different level of automation, reproducibility, and efficiency - one that sponsors with large-molecule programmes have come to recognise and request.
This blog post highlights Gyrolab as the LBA platform of choice for bioanalytical CROs serving the biotherapeutic market: what it delivers, why it matters commercially, and where it gives CROs a measurable advantage over competitors only running conventional plate-based methods.
Ten years ago, a bioanalytical CRO could build a credible large-molecule offering around optimized manual plate-based workflows, experienced analysts, and strong regulatory knowledge. That is no longer sufficient.
Today's sponsor is typically a mid-size biotech or emerging biopharma running a complex biologics programme - an ADC, a bispecific, a therapeutic protein in a difficult biological matrix - under pressure to generate IND-enabling data quickly and with limited internal bioanalytical capacity. They are outsourcing, not because they lack scientific knowledge, but because they lack bandwidth. They know what good data looks like, and what platforms exist, and they are choosing CRO partners based on the quality and reliability of the analytical workflow.
Specifically, sponsors are looking for:
Gyrolab meets all five criteria. Traditional plate-based immunoassays, including well-optimised ELISAs, often struggle to deliver the same level of consistency, automation and workflow efficiency. Manual plate-based assays can address many of these requirements but often require considerably more optimization and operator intervention.
For a CRO, assay development is often the critical path that determines how quickly a new project can begin. Sponsors increasingly expect methods to be developed, optimized, and transferred to validation within compressed timelines.
Gyrolab automated workflow, low reagent consumption and wide dynamic range enable scientists to screen more combinations of capture and detection reagents, buffer conditions and assay formats using a fraction of the sample and reagent required by traditional plate-based immunoassays. This allows optimization experiments that might require multiple plates over several days to be completed much more rapidly.
The practical benefit is that CROs can move from project initiation to validated assay in a shorter timeframe, allowing sample analysis studies to start earlier and reducing the overall time from assay development to reportable data. Faster method development also increases laboratory capacity, enabling scientific teams to support more customer projects without increasing headcount.
Because assay optimization is completed more rapidly and under highly reproducible automated conditions, CROs can progress into pre-validation and formal validation earlier, shortening overall project timelines.
For a bioanalytical CRO, reproducibility is not just a scientific requirement. It is the foundation of client trust. When a sponsor submits a regulatory package, the bioanalytical data your laboratory generated is part of that submission. If assay runs fail, if inter-analyst variability inflates error, or if a method that passed internal QC fails at a partner site, the consequences land on the sponsor's programme and on your reputation as a CRO.
Plate-based assay variability is well documented. Manual pipetting, plate-to-plate coating inconsistency, wash step timing, and incubation temperature gradients all contribute to run-to-run variation that even experienced bioanalytical scientists reduce but do not fully eliminate. In a regulated GLP study, where both FDA and ICH M10 bioanalytical guidance require that at least 75% of calibration standards meet ±20% of nominal (±25% at the LLOQ), and at least 67% of QC samples meet ±20% of nominal, this inherent variability is a direct source of run failure risk.
Gyrolab is designed to minimize variability, typically keeping it below 10%. Sample and reagent volumes are metered by the instrument. Incubation timing is software-controlled. Wash steps are executed uniformly across all positions. The analyst prepares the samples and loads the disc, the instrument does the rest.
The practical result for a CRO is fewer failed runs, fewer repeat analyses, and more consistent data across analysts, laboratory sites, and instruments. For a lab processing hundreds of samples per week across multiple sponsor programmes, this consistency saves a significant amount of analyst time and instrument capacity - in addition to the benefits for the sponsor.
A common and underappreciated pain point for CROs running preclinical PK and immunogenicity studies is sample volume. Rodent serial sampling produces small volumes. Studies designed under 3Rs principles - Replace, Reduce, Refine - are intentionally designed to minimize blood collection volumes. Sponsors increasingly expect multiple analytes to be measured from the same sample: total antibody PK, ADA screening, and a biomarker or two, all from a single timepoint collection.
With a standard plate based immunoassay consuming 25-100 µL per well, covering duplicates, standards, and QCs across multiple assay types from a single sample collection is often simply not feasible. Something has to give: either additional animals are used, or analytical coverage is reduced, or sample is diluted beyond the assay's reliable working range.
Gyrolab consumes 5 µL of sample per assay measurement. This is a significant improvement, it alters what is scientifically and operationally feasible. A single 50 µL bleed can support concurrent PK, ADA, and biomarker measurements that would require either a substantially larger blood volume or separate sampling timepoints if using a plate-based format.
For CROs, this translates directly into client value: study designs that are more ethically sound, more analytically comprehensive, and less likely to require protocol amendments when sample volumes turn out to be more limited than anticipated.
CRO sponsors measure performance mainly in two ways: (1) data quality and (2) turnaround time. The former determines whether they will trust you with regulated studies, the latter determines whether they will turn to your services again.
A single Gyrolab run processes 96 or 112 data points in approximately one hour, with minimal hands-on time during the run. For comparison, running a manual plate requires incubation steps that may extend overnight, and several hours of active handling. The throughput advantage of using Gyrolab is substantial, particularly for large immunogenicity screening or multi-timepoint PK studies where hundreds of samples arrive from a clinical site with a narrow time window for processing.
The throughput gain also has a direct impact on cost per sample. Fewer analyst hours per run, less reagent consumption per data point, and higher instrument utilization all improve the economics of running a Gyrolab-based LBA service relative to a plate-based one. For CROs competing on price as well as capability, this matters.
Perhaps more importantly for CRO business development: wide dynamic range on Gyrolab, spanning three to four orders of magnitude within a single run, reduces the number of dilution series required to bring samples into the assay window. Fewer dilutions means fewer manual steps, fewer sources of error, and faster time from receiving samples to reportable result.
For CROs running GLP preclinical studies and supporting Phase I and II clinical programmes, regulatory compliance is non-negotiable. The data generated in your laboratory becomes part of a regulatory submission. It must be reproducible, traceable, and generated under a quality system that regulators can audit.
Gyrolab supports regulated bioanalysis environments directly. The platform's software provides audit trails, controlled user access, and structured data handling consistent with 21 CFR Part 11 and equivalent international requirements. Automated workflows reduce the operator-dependent steps that are most difficult to document and defend in an audit context.
Critically, the same Gyrolab platform used in a fit-for-purpose research setting can support fully validated GLP bioanalysis without any change to the instrumentation. For a CRO managing client programmes across different development phases, this means assay methods developed in early research can be progressively qualified and validated on the same instrument, with documented continuity, reducing the method transfer burden and the risk of analytical differences emerging between development phases.
Meeting regulatory acceptance criteria is one part of the compliance picture. Getting there consistently, across runs and operators, is another. Because Gyrolab automates the steps that drive variability in manual immunoassays, sample and reagent delivery, incubation timing, wash performance, assay behaviour is more consistent from run to run. When a method is transferred between analysts, sites, or development phases, that consistency means fewer revalidation cycles, less troubleshooting, and greater confidence that the method arriving in a new laboratory will perform the same way it did in the original one.
When a sponsor's programme advances from preclinical and IND-enabling studies into clinical development, they look for a CRO that can demonstrate platform continuity - the same instrument, the same assay, and the same data quality from discovery through regulatory submission.
Antibody-drug conjugates (ADCs) are among the fastest-growing and most analytically demanding modalities in the current biotherapeutic pipeline. Sponsors running ADC programmes need bioanalytical CROs that can handle the full LBA package: total antibody, intact conjugated antibody (ADC), and anti-drug antibody (ADA) assays running in parallel, often across the same sample sets, throughout a clinical study. Gyrolab immunoassays are well-suited for ADC analysis. The assays need small sample and reagent volumes, the assay development is quick, which is especially beneficial when screening large numbers of reagents. In addition, Gyrolab is tolerant to a broad range of biological matrices.
Each assay type in an ADC programme has distinct technical requirements:
1. Total antibody assays measure all antibody species regardless of conjugation status, using target- or idiotype-based capture. Sensitivity and dynamic range requirements are demanding as drug concentrations span several orders of magnitude across a dosing interval.
2. Conjugated antibody assays selectively detect ADC species still carrying payload, requiring a payload- or linker-directed detection reagent alongside antibody capture. Assay specificity is critical, and matrix effects from released payload can complicate method development.
3. ADA bridging assays must detect patient immune responses in the presence of high circulating drug concentrations, requiring acid dissociation or drug-tolerant assay strategies to overcome drug interference.
Gyrolab supports all three assay formats with the sensitivity, reproducibility, and matrix tolerance that ADC programmes need. CROs that can offer a complete, in-house Gyrolab-based ADC bioanalytical package are in a stronger commercial position when competing for ADC business.
Free payload measurement, the unconjugated cytotoxic drug released from the linker, is a small molecule analyte best addressed by LC-MS rather than LBA. A complete ADC bioanalytical service integrates Gyrolab for the immunoassay components with LC-MS for payload quantification. CROs offering both capabilities under one roof are best placed to serve ADC sponsors comprehensively.
One of the most overlooked commercial arguments for Gyrolab at a CRO is platform continuity. Many CRO clients begin their relationship in early development, fit-for-purpose PK assays, exploratory immunogenicity screening, and research-grade biomarker work. As their programme advances, the analytical requirements formalize: GLP validation, regulatory-grade documentation, method transfer packages for clinical phase work.
Gyrolab supports all stages. A fit-for-purpose assay developed in a discovery context can be progressively qualified and ultimately fully validated on the same instrument, using the same assay parameters, with documented continuity throughout.
If your laboratory uses plate based assays for early work and then transitions to a validated platform for regulated studies, every programme that crosses that boundary requires a method transfer, a bridging study, and a documented rationale for any analytical differences between the two methods. This is time-consuming, introduces risk, and creates uncertainty for the sponsor at a point in their programme where they have little tolerance for delay.
Investing in Gyrolab is not simply an instrumentation decision. It is a positioning decision. CROs that run Gyrolab are better placed to:
The competitive pressure on bioanalytical CROs serving the biotherapeutic market will only increase as pipelines become more complex and sponsors become more selective. Gyrolab is the LBA platform that positions a CRO to meet that evolving market. Gyrolab doesn't just run assays faster than traditional plate-based methods, it enables CROs to develop, optimise, validate and deliver bioanalytical methods much more quickly, allowing sponsors to progress their programmes sooner.
Ready to talk about what Gyrolab could do for your lab?
Become a certified CRO partner
Download brochure: Scale your lab. Deliver Reliable data.